• Target


  • Type


  • Close Date

    Jun 30 2019

  • Status


RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.

Living With

Living With develops smart condition management apps, used by healthcare providers which improve patient outcomes and save costs.

Investment closes only once the total pledged amount passes the minimum of £150,000

Total Pledged: £158,000


A pledge is not a commitment. You will be asked to confirm in the next section.



Living With aims to make it easy and cost effective for any clinician to create their own “off the shelf” smart medical apps, to connect to and monitor their patients remotely, helping to improve outcomes and reduce clinician costs. Living With will be the first to market with a build-your-own condition management platform.

There is a large and diverse set of healthcare professionals, clinics and providers who want to launch their own condition management products for patients and end users across 1000’s of conditions, both in the UK and internationally.

This includes insurers, pharmaceutical companies, researchers, hospitals, private clinics, hospital consultants, allied health professionals and charities. In the UK there are 220 NHS and 200+ private hospitals, 200+ CCG’s, 47,816 hospital consultants and 172,688 allied health professionals. This is growing year on year. There are 1.8 million physicians working in the EU and over 7000 hospitals. 

Today Living With has a single condition management software platform with 3 live products & 1 in development: 

  • Squeezy the UK’s top paid medical app with 127,000 downloads, to help patients to do their pelvic floor exercises 

  • Living With Pelvic Health (LWPH) for physiotherapy, enables clinics to provide patients with bladder and bowel issues with a free and connected version of Squeezy and monitor them remotely. It is live in 12 NHS Trusts and 4 private clinics (UK & CH) and is now extending into higher value conditions e.g. urology and colorectal. 

  • Living With Rheumatoid Arthritis (LWRA), is in 1 NHS trust, and going live in 2 more. The company has also won a £320k Innovate UK grant to develop an AI based flare profiler. 

  • Living With Lupus (LWL) is in development with a pharma company, for use internationally in multiple languages. 

Ultimately the company’s vision is to have 1000’s of apps in use by healthcare providers across the world on its “build-your-own” self-service condition management platform, providing advice and predictive treatment plans.

The company is currently raising a 2nd round of £350,000 in EIS funding to develop a first version of its build-your-own platform, get a 3rd condition live, namely Living With Lung cancer, with Bart’s NHS Trust and finish the next stage of LWRA product development to close some new paying customers. The company is planning to do an institutional fundraise in late 2019.

The company expects to earn £1.07m of revenues by year end March 31st, 2019. 
Deal Manager avatar

Deal Manager
Nick Taylor

  • Sector: Technology / IT / Software
  • Region: UK: London
  • Stage: Early stage - early revenues, pre-profit
  • Eligible Tax: EIS
  • Board Requirement: Will consider further board appointments
  • Pre Money Valuation: £2,200,000
  • Share Price: £12.97
  • Originator: Envestors
This section is currently locked.
Please Sign Up or Log In to unlock.

Lead Investor

Surrey 2 1331114864

Lars McBride

“The healthcare market is moving ever faster towards enabling patients to take more control of the management and treatment of their conditions and to providing opportunities for ‘treatment at a distance’. With their long experience with Squeezy, Living With is well placed to benefit from this trend and to develop the products that enable this. Getting into 12 NHS Trusts in 12 months and developing the breadth of prospects that they have in their pipeline, is testament to their ability to grow a company. The business is eminently scalable, both by product and geography.” -- Lars McBride , 1st Round Investor


This section is currently locked.
Please Sign Up or Log In to unlock.


This section is currently locked.
Please Sign Up or Log In to unlock.


This section is currently locked.
Please Sign Up or Log In to unlock.


This section is currently locked.
Please Sign Up or Log In to unlock.


This section is currently locked.
Please Sign Up or Log In to unlock.


Originator: Envestors

Investment Focus: Equity and Debt

About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.

Contact Name: Oliver Woolley

  • Registered Investors
    Over 1000
  • Investment through platform
    Over £100m